Abbott Laboratories

ABT

$110.27

-8.3% last 12 months

Polen Capital Holding value: $1.7 Billion Ken Fisher Holding value: $1.04 Billion Jim Simons Holding value: $346 Million Ray Dalio Holding value: $336 Million Jeremy Grantham Holding value: $182 Million Ken Griffin Holding value: $91.1 Million Joel Greenblatt Holding value: $12.2 Million Mario Gabelli Holding value: $2.62 Million Tom Russo Holding value: $1.3 Million Steven Cohen Holding value: $0 Chuck Akre Holding value: $0 Tom Gayner Holding value: $0 Daniel Loeb Holding value: $0 Chris Davis Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Bill Gates Holding value: $0 Donald Yacktman Holding value: $0 David Tepper Holding value: $0 Prem Watsa Holding value: $0

Market Cap

$192 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$100.79 - $140.91

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

22.46x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.85 (1.68%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $192 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $200 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $1.85 (1.68%)
1 Year Return Profit or loss of share price change plus dividend yield. -6.6%
52-Week High Highest share price in the last 52 weeks. $140.91
52-Week Low Lowest share price in the last 52 weeks. $100.79
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.77
Outstanding Shares The number of shares the company has issued and are held by stockholders. 1.75 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 4.53 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 22.46
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 32.22
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $4.81
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.24
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.51
Enterprise Value to Revenue Enterprise value divided by revenue 4.38
Enterprise Value to EBIT Enterprise Value divided by EBIT 19.55
Total Debt to Enterprise Value Total debt divided by enterprise value 0.08
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.46

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $45.5 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $26.4 Billion
EBIT Earnings before tax and interest payments. $10.2 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $8.55 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 18.78%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +69.7%
Return on Equity Equity divided by market cap. 23.44%
Return on Assets Indicates a company's profitability in relation to its total assets. 11.53%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 16.52%

Insider trades

No purchases

90,200.0 shares sold (5 transactions)

No purchases

4,462.0 shares sold (2 transactions)

No purchases

No sells

No purchases

No sells

Q4 2021 Q1 2022 Q2 2022 Q3 2022

About Abbott Laboratories

CEO: Robert Ford

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Johnson & Johnson
Johnson & Johnson
Pfizer Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Hologic, Inc.
Hologic, Inc.
Medtronic Plc
Medtronic Plc
Boston Scientific Corp.
Boston Scientific Corp.
Astrazeneca plc - ADR
Astrazeneca plc - ADR
Novartis AG - ADR
Novartis AG - ADR
Glaxosmithkline plc - ADR
Glaxosmithkline plc - ADR

News

Abbott Labs'' Dividend Strength Is Top Notch (NYSE:ABT)

Abbott Labs'' Dividend Strength Is Top Notch (NYSE:ABT)

Dividend Aristocrat Abbott Laboratories is one of our favorite healthcare names.

Seeking Alpha Seeking Alpha, 1 day ago
Abbott Laboratories: A Lesser Johnson & Johnson? (NYSE:ABT)

Abbott Laboratories: A Lesser Johnson & Johnson? (NYSE:ABT)

Similar to JNJ, ABT is a broadly diversified medical device and healthcare company. It has received much attention for its strong performance during the pand...

Seeking Alpha Seeking Alpha, 7 days ago
Blood Screening Market Estimated to Experience a Hike in Growth by 2021-2031 | Grifols , F. Hoffmann-La Roche Ltd., Abbott Laboratories, Inc., bioMérieux

Blood Screening Market Estimated to Experience a Hike in Growth by 2021-2031 | Grifols , F. Hoffmann-La Roche Ltd., Abbott Laboratories, Inc., bioMérieux

The blood screening market size was USD 2.8 billion in 2021 and it is anticipated to reach USD 5.5 billion in 2031, growing at a CAGR of 6.9% from 2022-2031....

OpenPR OpenPR, 9 days ago
If You Invested $25,000 in Abbott Laboratories in 2013, This Is How Much You Would Have Today

If You Invested $25,000 in Abbott Laboratories in 2013, This Is How Much You Would Have Today

The real question may be, has Abbott been a better buy than AbbVie since the spinoff?

The Motley Fool The Motley Fool, 11 days ago
Never miss a trade
To improve your user experience we use cookies.